Conditions of primary excessive daytime sleepiness.

Excessive daytime somnolence is a prevalent problem in medical practice and in society. It exacts a great toll in quality of life, personal and public safety, and productivity. The causes of EDS are myriad, and careful evaluation is needed to determine the cause in each case. Although much progress has been made in discovering the pathophysiology of narcolepsy, much more remains to be understood, and far less is known about other primary conditions of EDS. Several methods have been developed to assess EDS, although each of them has limitations. Treatment is available for the great majority of cases.

[1]  W Dement,et al.  The nature of the narcoleptic sleep attack , 1966, Neurology.

[2]  T. Roth,et al.  The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. , 1996, Sleep.

[3]  F. Rosenow,et al.  Multiple Sleep Latency Test and Polysomnography in Diagnosing Kleine–Levin Syndrome and Periodic Hypersomnia , 2000, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[4]  J. Montplaisir,et al.  Narcolepsy and idiopathic hypersomnia , 1982, Neurology.

[5]  Christian Guilleminault,et al.  Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy , 2000, Neurology.

[6]  V. Pankratz,et al.  Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. , 2002, Sleep.

[7]  Susan Lines Alaia.  Life effects of narcolepsy : measures of negative impact, social support, and psychological well-being , 1989 .

[8]  R. Manni,et al.  Evaluation of sleepiness in epilepsy , 2000, Clinical Neurophysiology.

[9]  C. Guilleminault,et al.  Mononucleosis and Chronic Daytime Sleepiness: A Long-term Follow-up Study , 1986 .

[10]  Michael Aldrich,et al.  Reduced Number of Hypocretin Neurons in Human Narcolepsy , 2000, Neuron.

[11]  E. Mignot,et al.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. , 2002, Archives of neurology.

[12]  H. Persson,et al.  Menstruation‐related periodic hypersomnia , 1982, Neurology.

[13]  J. Montplaisir,et al.  Homeostatic sleep regulation in patients with idiopathic hypersomnia , 2000, Clinical Neurophysiology.

[14]  E. Mignot,et al.  Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans , 2000, Neuroscience Research.

[15]  G. Francisco,et al.  Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report. , 1996, American journal of physical medicine & rehabilitation.

[16]  F. Bouquet,et al.  Endozepine Stupor in Children , 1997, Cephalalgia : an international journal of headache.

[17]  J. Montplaisir,et al.  HLA in Disorders of Excessive Daytime Sleepiness Without Cataplexy in Canada , 1988 .

[18]  M. Kryger,et al.  Principles and Practice of Sleep Medicine , 1989 .

[19]  T. Pollmächer,et al.  Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy , 2001 .

[20]  R. Chervin,et al.  Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea. , 2000, American journal of respiratory and critical care medicine.

[21]  R. Chervin,et al.  Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. , 1997, Sleep.

[22]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[23]  E. Mignot,et al.  PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY , 1997, Progress in Neurobiology.

[24]  S. Chokroverty.  Sleep and degenerative neurologic disorders. , 1996, Neurologic clinics.

[25]  M. Critchley.  [The syndrome of hypersomnia and periedical megapgagia in the adult male (Kleine-Levin): what is its natural course?]. , 1967, Revue neurologique.

[26]  B. Roth,et al.  Narcolepsy and Hypersomnia , 1981 .

[27]  Y. Honda.  Clinical Features of Narcolepsy: Japanese Experiences , 1988 .

[28]  S. Maret,et al.  Clinical efficacy of high‐dose intravenous immunoglobulins near the onset of narcolepsy in a 10‐year‐old boy , 2003, Journal of sleep research.

[29]  J. W. Gibbs,et al.  Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. , 2002, Sleep.

[30]  M. Satake,et al.  HLA antigens in Japanese patients with narcolepsy , 1984 .

[31]  C. Guilleminault,et al.  Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia , 1983, Annals of neurology.

[32]  Jon T. Willie,et al.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness. , 2001, Annual review of neuroscience.

[33]  C. Guilleminault,et al.  Hypnagogic and Hypnopompic Hallucinations: Pathological Phenomena? , 1996, British Journal of Psychiatry.

[34]  H. Kraemer,et al.  Stability of cataplexy over several months--information for the design of therapeutic trials. , 1994, Sleep.

[35]  G. Tunnicliff.  Gamma-Hydroxybutyrate: Molecular, functional and clinical aspects , 2002 .

[36]  E. Mignot,et al.  Hypocretin Levels in Sporadic and Familial Cases of Canine Narcolepsy , 2001, Neurobiology of Disease.

[37]  M. Arias,et al.  Síndrome de Kleine-Levin: aportaciÓn diagnÓstica de la SPECT cerebral , 2002 .

[38]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[39]  M. Aldrich.  The clinical spectrum of narcolepsy and idiopathic hypersomnia , 1996, Neurology.

[40]  D. Fry,et al.  Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy , 1998, Annals of neurology.

[41]  C Guilleminault,et al.  A cause of excessive daytime sleepiness. The upper airway resistance syndrome. , 1993, Chest.

[42]  E. Mignot,et al.  Genetic and familial aspects of narcolepsy , 1998, Neurology.

[43]  C. Guilleminault,et al.  A study on cataplexy. , 1974, Archives of neurology.

[44]  T. Juji,et al.  HLA in Narcolepsy , 1988, Springer Berlin Heidelberg.

[45]  R Broughton,et al.  Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. , 1986, Sleep.

[46]  J. Touchon,et al.  Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset , 2004, Annals of neurology.

[47]  E. Mignot,et al.  Late‐onset narcolepsy presenting as rapidly progressing muscle weakness: Response to plasmapheresis , 2005, Annals of neurology.

[48]  J. Askenasy,et al.  Sleep in Parkinson’s Disease , 2022, Sleep and Neuropsychiatric Disorders.

[49]  Emmanuel Mignot,et al.  The role of hypocretins (orexins) in sleep regulation and narcolepsy. , 2002, Annual review of neuroscience.

[50]  Sebastiaan Overeem,et al.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains , 2000, Nature Medicine.

[51]  R. Sangal,et al.  P300 Latency: Abnormal in Sleep Apnea with Somnolence and Idiopathic Hypersomnia, but Normal in Narcolepsy , 1995, Clinical EEG.

[52]  D. Bruck,et al.  A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[53]  A E Rogers,et al.  Health-related quality of life effects of modafinil for treatment of narcolepsy. , 1999, Sleep.

[54]  C. Guilleminault,et al.  Monoamine interactions in narcolepsy and hypersomnia: a preliminary report. , 1986, Sleep.

[55]  M. Aldrich,et al.  Idiopathic hypersomnia : A series of 42 patients , 1997 .

[56]  C. Trenkwalder.  Sleep dysfunction in Parkinson's disease. , 1998, Clinical neuroscience.

[57]  E. Mignot,et al.  Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. , 2003, Sleep.

[58]  C. Guilleminault,et al.  A menstruation-linked periodic hypersomnia , 1975, Neurology.

[59]  E. Mignot,et al.  Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives , 2001, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[60]  C. Bamford.  Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide. , 1993, Sleep.

[61]  G. Koob,et al.  Narcolepsy and its treatment with stimulants. ASDA standards of practice. , 1994, Sleep.

[62]  G. Plazzi,et al.  Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation. , 1998, Brain : a journal of neurology.

[63]  M. Billiard,et al.  CSF immune variables in patients with narcolepsy , 1990, Acta neurologica Scandinavica.

[64]  A. Guidotti,et al.  Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor , 1992, The Lancet.

[65]  M. Lovett,et al.  Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Y. Inoue,et al.  CSF hypocretin‐1 (orexin‐A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia , 2002, Journal of sleep research.

[67]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[68]  A. N. van den Pol,et al.  Neurons Containing Hypocretin (Orexin) Project to Multiple Neuronal Systems , 1998, The Journal of Neuroscience.

[69]  K. Ishihara,et al.  High prevalence of isolated sleep paralysis: kanashibari phenomenon in Japan. , 1987, Sleep.

[70]  T. Juji,et al.  Immunological Features of Narcolepsy in Japan , 1988 .

[71]  A. Rechtschaffen,et al.  Hypersomnia with "sleep drunkenness". , 1972, Archives of general psychiatry.

[72]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[73]  S Koskimies,et al.  The prevalence of narcolepsy: An epidemiological study of the Finnish Twin Cohort , 1994, Annals of neurology.